Iovance Q1 revenue $71M (+45% YoY); guides FY26 $350-370M; endometrial cancer 40% cORR

IOVANCE BIOTHERAPEUTICS, INC.

2026-Q1 EPS reported -$0.19 revenue$71,430,000

Total product revenue ~$71M in Q1 2026, up 45% YoY; U.S. Amtagvi revenue ~$60M, Proleukin ~$11M.
FY 2026 revenue guidance $350-$370M; Q2 2026 guidance $86-$88M.
Lifileucel in metastatic serous endometrial cancer: 40% confirmed ORR, 100% DCR in first 5 patients; FDA expedited path planned.
Cash ~$319M, expected to fund operations into 2028; R&D expenses down 12% vs Q4 2025.
UK MAA for lifileucel withdrawn for procedural reasons, will resubmit; EMA resubmission planned for 2026.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

IOVANCE BIOTHERAPEUTICS, INC. reported Full year 2026 results: revenue $350 million to $370 million. Guidance initiated.

Period: Full year 2026
Revenue: $350 million to $370 million
Guidance: initiated
Result: guidance update

Exact text from the filing

Total product revenue guidance for 2Q26 is $86 million to $88 million and for FY26 is $350 million to $370 million

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

IOVANCE BIOTHERAPEUTICS, INC. reported Second quarter 2026 results: revenue $86 million to $88 million. Guidance initiated.

Period: Second quarter 2026
Revenue: $86 million to $88 million
Guidance: initiated
Result: guidance update

Exact text from the filing

Total product revenue guidance for 2Q26 is $86 million to $88 million

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

IOVANCE BIOTHERAPEUTICS, INC. reported first quarter ended March 31, 2026 results: revenue ~$71 million.

Period: first quarter ended March 31, 2026
Revenue: ~$71 million
Result: reported results

Exact text from the filing

and long-term value for patients and shareholders.” First Quarter 2026 Financial Highlights Continued Strength in Execution and Cost Discipline · Total product revenue of ~$71 million increased by ~45% over 1Q25, reflecting significant performance improvements over the prior annual maintenance period. o U.S. Amtagvi revenue was ~$60 million. o Global

View on SEC.gov

51 earnings releases filed in the last 30 days. Browse all earnings releases →

IOVANCE BIOTHERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0001104659-26-056782

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.